- Home
- CRVS vs DAVA Comparison
CRVS vs DAVA Comparison
Compare CRVS & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- DAVA
- Stock Information
- Founded
- CRVS 2014
- DAVA 2000
- Country
- CRVS United States
- DAVA United Kingdom
- Employees
- CRVS N/A
- DAVA N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- DAVA EDP Services
- Sector
- CRVS Health Care
- DAVA Technology
- Exchange
- CRVS Nasdaq
- DAVA Nasdaq
- Market Cap
- CRVS 459.0M
- DAVA 503.6M
- IPO Year
- CRVS 2016
- DAVA 2018
- Fundamental
- Price
- CRVS $8.04
- DAVA $9.27
- Analyst Decision
- CRVS Strong Buy
- DAVA Buy
- Analyst Count
- CRVS 4
- DAVA 8
- Target Price
- CRVS $13.75
- DAVA $22.38
- AVG Volume (30 Days)
- CRVS 1.1M
- DAVA 916.2K
- Earning Date
- CRVS 11-04-2025
- DAVA 11-11-2025
- Dividend Yield
- CRVS N/A
- DAVA N/A
- EPS Growth
- CRVS N/A
- DAVA 24.14
- EPS
- CRVS N/A
- DAVA 0.49
- Revenue
- CRVS N/A
- DAVA $1,058,028,497.00
- Revenue This Year
- CRVS N/A
- DAVA N/A
- Revenue Next Year
- CRVS N/A
- DAVA $3.81
- P/E Ratio
- CRVS N/A
- DAVA $18.79
- Revenue Growth
- CRVS N/A
- DAVA 4.25
- 52 Week Low
- CRVS $2.54
- DAVA $8.17
- 52 Week High
- CRVS $10.00
- DAVA $34.94
- Technical
- Relative Strength Index (RSI)
- CRVS 64.17
- DAVA 49.28
- Support Level
- CRVS $7.46
- DAVA $8.55
- Resistance Level
- CRVS $7.96
- DAVA $9.88
- Average True Range (ATR)
- CRVS 0.56
- DAVA 0.38
- MACD
- CRVS 0.01
- DAVA 0.16
- Stochastic Oscillator
- CRVS 75.46
- DAVA 64.33
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.